The fertility benefits manager raised its full-year guidance after reporting Q1 2026 results, signaling stronger demand.
Progyny updated its 2026 financial outlook, projecting revenue between $1.365 billion and $1.405 billion, up from prior expectations. Adjusted EBITDA is now forecast at $232 million to $244 million, reflecting improved operational performance.
The revised guidance follows Q1 2026 results, which management discussed in an earnings call. The company had not previously disclosed specific 2026 targets, making this the first formal projection for the year.
Shares of Progyny showed limited immediate reaction to the announcement, as investors await further details on growth drivers.